Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study

Martien Wampers; Linda Hanssens; Ruud van Winkel; Adrian Heald; Julien Collette; Joseph Peuskens; Jean-Yves Reginster; Andre Scheen; Marc De Hert

doi:10.1016/j.euroneuro.2011.03.010

Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study

Martien Wampers, Linda Hanssens, Ruud van Winkel, Adrian Heald, Julien Collette, Joseph Peuskens, Jean-Yves Reginster, Andre Scheen, Marc De Hert^*

^*Corresponding author for this work

MHeNs School for Mental Health and Neuroscience

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	17-26
Journal	European Neuropsychopharmacology
Volume	22
Issue number	1
DOIs	https://doi.org/10.1016/j.euroneuro.2011.03.010
Publication status	Published - Jan 2012

Keywords

Adiponectin
Antipsychotic
Diabetes
Metabolic side-effects
Metabolic syndrome
Schizophrenia

Access to Document

10.1016/j.euroneuro.2011.03.010

Cite this

Wampers, M., Hanssens, L., van Winkel, R., Heald, A., Collette, J., Peuskens, J., Reginster, J-Y., Scheen, A., & De Hert, M. (2012). Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study. European Neuropsychopharmacology, 22(1), 17-26. https://doi.org/10.1016/j.euroneuro.2011.03.010

Wampers, Martien ; Hanssens, Linda ; van Winkel, Ruud ; Heald, Adrian ; Collette, Julien ; Peuskens, Joseph ; Reginster, Jean-Yves ; Scheen, Andre ; De Hert, Marc. / Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study. In: European Neuropsychopharmacology. 2012 ; Vol. 22, No. 1. pp. 17-26.

@article{0aeab9ea236d4d84935aed4b27389f51,

title = "Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study",

keywords = "Adiponectin, Antipsychotic, Diabetes, Metabolic side-effects, Metabolic syndrome, Schizophrenia",

author = "Martien Wampers and Linda Hanssens and {van Winkel}, Ruud and Adrian Heald and Julien Collette and Joseph Peuskens and Jean-Yves Reginster and Andre Scheen and {De Hert}, Marc",

year = "2012",

month = jan,

doi = "10.1016/j.euroneuro.2011.03.010",

language = "English",

volume = "22",

pages = "17--26",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier",

number = "1",

}

Wampers, M, Hanssens, L, van Winkel, R, Heald, A, Collette, J, Peuskens, J, Reginster, J-Y, Scheen, A & De Hert, M 2012, 'Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study', European Neuropsychopharmacology, vol. 22, no. 1, pp. 17-26. https://doi.org/10.1016/j.euroneuro.2011.03.010

Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study. / Wampers, Martien; Hanssens, Linda; van Winkel, Ruud; Heald, Adrian; Collette, Julien; Peuskens, Joseph; Reginster, Jean-Yves; Scheen, Andre; De Hert, Marc.

In: European Neuropsychopharmacology, Vol. 22, No. 1, 01.2012, p. 17-26.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study

AU - Wampers, Martien

AU - Hanssens, Linda

AU - van Winkel, Ruud

AU - Heald, Adrian

AU - Collette, Julien

AU - Peuskens, Joseph

AU - Reginster, Jean-Yves

AU - Scheen, Andre

AU - De Hert, Marc

PY - 2012/1

Y1 - 2012/1

KW - Adiponectin

KW - Antipsychotic

KW - Diabetes

KW - Metabolic side-effects

KW - Metabolic syndrome

KW - Schizophrenia

U2 - 10.1016/j.euroneuro.2011.03.010

DO - 10.1016/j.euroneuro.2011.03.010

M3 - Article

C2 - 21511441

VL - 22

SP - 17

EP - 26

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 1

ER -